Review
Oncology
Wei Zhang, Bixiang Zhang, Xiao-ping Chen
Summary: Several adjuvant treatments have been evaluated for preventing HCC recurrence after curative liver resection, with antiviral therapy and postoperative adjuvant transarterial chemoembolization showing promising results. However, further large-scale randomized controlled trials are needed to confirm their efficacy in different patient populations.
FRONTIERS OF MEDICINE
(2021)
Article
Medicine, General & Internal
Hamzah Adwan, Lars Hammann, Thomas J. Vogl
Summary: This study evaluated the efficacy and safety of microwave ablation (MWA) as a treatment for recurrent hepatocellular carcinoma (HCC) after initial surgical resection. The results showed that MWA treatment is effective and safe for recurrent HCC lesions.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Mauro Giuffre, Enrico Zuliani, Alessia Visintin, Paola Tarchi, Paola Martingano, Riccardo Pizzolato, Deborah Bonazza, Flora Masutti, Rita Moretti, Lory Saveria Croce
Summary: This study aims to determine factors associated with early recurrence of hepatocellular carcinoma (HCC). The results indicate that male gender and larger tumor nodules are the main risk factors for early HCC recurrence.
Article
Oncology
Hideko Ohama, Atsushi Hiraoka, Fujimasa Tada, Kanako Kato, Yoshiko Fukunishi, Emi Yanagihara, Masaya Kato, Hironobu Saneto, Hirofumi Izumoto, Hidetaro Ueki, Takeaki Yoshino, Shogo Kitahata, Tomoe Kawamura, Taira Kuroda, Yoshifumi Suga, Hideki Miyata, Masashi Hirooka, Masanori Abe, Bunzo Matsuura, Tomoyuki Ninomiya, Yoichi Hiasa
Summary: This study compared the therapeutic efficacy differences between surgical resection and radiofrequency ablation for initial recurrent early-stage hepatocellular carcinoma. The results showed no significant differences in regard to recurrence-free survival or overall survival between the two treatment methods.
Article
Gastroenterology & Hepatology
Yanyan Ye, Ying Wang, Haoqian Xu, Fengming Yi
Summary: This study conducted a network meta-analysis to compare the efficacy of different treatments for preventing recurrence and prolonging survival in hepatocellular carcinoma patients. The results showed that transarterial chemoembolization (TACE) + portal vein chemotherapy (PVC) and internal radiotherapy (IRT) were effective in reducing recurrence rate, while TACE, IRT, and dendritic cell (DC) treatments showed benefits in extending the patients' survival time.
BMC GASTROENTEROLOGY
(2023)
Review
Oncology
Bin Guo, Qian Chen, Zhicheng Liu, Xiaoping Chen, Peng Zhu
Summary: Curative surgical treatments, such as liver resection, are still optimal options for hepatocellular carcinoma patients. However, the high recurrence rate within 5 years after surgery, especially in high-risk patients who experience early recurrence, calls for effective adjuvant therapy. Adjuvant transarterial chemoembolization, antiviral treatment, and traditional Chinese medicine have shown potential in preventing recurrence, but standardized postoperative management protocols are lacking.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Salvatore Gruttadauria, Floriana Barbera, Pier Giulio Conaldi, Duilio Pagano, Rosa Liotta, Enrico Gringeri, Roberto Miraglia, Gaetano Burgio, Marco Barbara, Giada Pietrosi, Calogero Camma, Fabrizio Di Francesco
Summary: Hepatocellular carcinoma (HCC) recurrence is a major issue post liver resection, with clinical factors and loss of heterozygosity in the PTEN locus playing a role in predicting and potentially reducing the risk of recurrence. Multiple cancer gene alterations are associated with HCC progression, with specific AI mutations presenting a protective effect on recurrence risk.
Article
Oncology
Huayong Cai, Wenxin Li, Yu Zhang, Xiangdong Hua
Summary: This study aimed to explore the potential relationship between tumor abnormal protein (TAP) and the prognosis of hepatocellular carcinoma (HCC) after a radical hepatectomy. The results showed that higher TAP was associated with poor prognosis. The study established a prognostic scoring system that can help assess the recurrence-free survival of postoperative HCC patients.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
(2022)
Article
Oncology
Cyprien Toubert, Boris Guiu, Bader Al Taweel, Eric Assenat, Fabrizio Panaro, Francois-Regis Souche, Jose Ursic-Bedoya, Francis Navarro, Astrid Herrero
Summary: Surgical resection is the optimal treatment for hepatocellular carcinoma (HCC), but recurrence is common. This retrospective study analyzed survival after HCC recurrence following liver resection. The time and type of recurrence treatment were found to be major prognostic factors. However, overall survival did not significantly differ between patients who experienced recurrence and those who did not after receiving curative treatment.
Article
Surgery
Hayato Abe, Yutaka Midorikawa, Tokio Higaki, Shintaro Yamazaki, Osamu Aramaki, Hisashi Nakayama, Masamichi Moriguchi, Tatsuo Kanda, Mitsuhiko Moriyama, Masahiro Okada, Haruna Nishimaki, Masahiko Sugitani, Shingo Tsuji, Tadatoshi Takayama
Summary: This study found that preoperative liver stiffness measurement using magnetic resonance elastography can predict intrahepatic recurrence after curative resection for hepatocellular carcinoma, and it was identified as an independent predictor along with vascular invasion.
Article
Oncology
Diamantis I. Tsilimigras, J. Madison Hyer, Adrian Diaz, Fabio Bagante, Francesca Ratti, Hugo P. Marques, Olivier Soubrane, Vincent Lam, George A. Poultsides, Irinel Popescu, Sorin Alexandrescu, Guillaume Martel, Aklile Workneh, Alfredo Guglielmi, Tom Hugh, Luca Aldrighetti, Itaru Endo, Timothy M. Pawlik
Summary: Both TBS and serum AFP are important predictors of prognosis among patients with resectable HCC. They have a synergistic impact on prognosis, with higher serum AFP predicting worse outcomes among patients with HCC of a certain TBS class.
Article
Biochemistry & Molecular Biology
Julu Huang, Rong Liang, Cheng Lu, Lu Lu, Shuanghang Li, Minchao Tang, Xi Huang, Shilin Huang, Rongyun Mai, Xing Gao, Shizhuo Li, Can Zeng, Yan Lin, Jiazhou Ye
Summary: Hepatocellular carcinoma (HCC) is a highly malignant digestive system tumor with complex underlying causes and significant post-surgery recurrence. The approval of sorafenib and PD-L1 inhibitors for HCC signifies a new era of immunotherapy and targeted treatment for this condition. Understanding the mechanisms of targeted immune combination therapy is crucial for the prospective management of HCC patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Christopher W. Ryan, Catherine M. Tangen, Elisabeth Heath, Mark N. Stein, Maxwell Meng, Ajjai S. Alva, Sumanta K. Pal, Igor Puzanov, Joseph Clark, Toni K. Choueiri, Neeraj Agarwal, Robert G. Uzzo, Naomi B. Haas, Timothy W. Synold, Melissa Plets, Ulka N. Vaishampayan, Brian M. Shuch, Ian M. Thompson Jr, Primo N. Lara Jr
Summary: Postoperative administration of everolimus did not show improvement in recurrence-free survival compared to placebo for renal cell carcinoma patients at high risk of recurrence after nephrectomy. These results do not provide support for the adjuvant use of everolimus in the treatment of renal cell carcinoma following surgery.
Article
Surgery
Jan Bednarsch, Zoltan Czigany, Lara R. Heij, Iakovos Amygdalos, Daniel Heise, Philip Bruners, Tom F. Ulmer, Ulf P. Neumann, Sven A. Lang
Summary: Resection for recurrent HCC (rHCC) is technically feasible and safe, with perioperative and postoperative outcomes similar to primary HCC patients. Therefore, re-resection should be considered for European patients diagnosed with rHCC.
LANGENBECKS ARCHIVES OF SURGERY
(2022)
Review
Oncology
Jiarui Yang, Hao Liang, Kunpeng Hu, Zhiyong Xiong, Mingbo Cao, Zhaozhong Zhong, Zhicheng Yao, Meihai Deng
Summary: pa-TACE, postoperative radiotherapy, and sorafenib can improve the prognosis of patients with hepatocellular carcinoma with microvascular invasion after curative resection compared to postoperative conservative treatment. Postoperative radiotherapy can reduce the recurrence of patients with HCC with MVI after curative resection when compared to pa-TACE.
CANCER CELL INTERNATIONAL
(2021)
